RxDoctor Payments DataLook up a doctor →

Dorothy Lacombe, NP

Adult Health · Latham, NYNPI 1780008078

Payments from drug & device makers

$45,907in general payments, 2019–2025

Across 1,293 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$18K
  • Janssen Scientific Affairs, LLC$10K
  • AbbVie$3K
  • UCB, Inc.$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • Pfizer$2K
  • plus $9K from 43 others

What the payments were for

  • Speaking & faculty fees$25,68156%
  • Food & beverage$19,67043%
  • Education$5561%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,907 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$2,267,834
Medicare patients
425
Services billed
162,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab111$837,065
RinvoqUpadacitinib85$585,602
Cimzia (2 Pack)Certolizumab Pegol22$254,209
Xeljanz XrTofacitinib Citrate28$249,650
Skyrizi PenRisankizumab-Rzaa11$219,519
TremfyaGuselkumab16$213,825
KevzaraSarilumab48$205,179
Cosentyx Sensoready PenSecukinumab18$140,341
Taltz AutoinjectorIxekizumab19$137,559
OtezlaApremilast27$134,212
XeljanzTofacitinib Citrate21$129,373
Orencia ClickjectAbatacept12$74,837
OrenciaAbatacept/Maltose13$74,712
Hydroxychloroquine Sulfate948$30,781
Celecoxib231$11,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,085$585,60285 claims
UCB, Inc.Cimzia (2 Pack)$2,571$254,20922 claims
Johnson & JohnsonTremfya$17,716$213,82516 claims
SanofiKevzara$317$205,17948 claims
AmgenOtezla$1,260$134,21227 claims
PfizerXeljanz$1,648$129,37321 claims
E.r. Squibb & Sons, L.L.C.Orencia$268$74,71213 claims
Antares Pharma, Inc.Otrexup$60$9,61613 claims
Scilex Pharmaceuticals Inc.Colchicine$197$8,56752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Latham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →